Accurate Diagnostic: The promise of NGS
Next-Generation Sequencing (NGS) has significantly impacted cancer diagnostics, enabling the identification of novel cancer mutations, personalized treatment, and improved clinical diagnosis. NGS has been widely applied in clinical oncology for cancer prevention, diagnosis, and treatment. It has facilitated the identification of novel and rare somatic mutations in various cancers, including blood cancer, renal cell carcinoma, and lung cancer.
Additionally, NGS has been used to sequence known cancer genes, identify genetic susceptibility, and define therapeutic vulnerabilities of cancer, leading to its rapid translation from discovery to clinical platform. In the context of advanced non-small cell lung cancer, NGS using circulating tumor DNA has shown high diagnostic accuracy, making it a reliable alternative for guiding patients to the right treatment based on their molecular profile. The implementation of NGS in a clinical setting offers exciting possibilities, such as rapidly screening numerous gene targets at minimal cost and revolutionizing cancer treatment through the emergence of small molecule inhibitors and antibodies against druggable gene targets.
NGS's ability to assess multiple genes in a single assay eliminates the need for ordering multiple tests to identify the causative mutation, making it a valuable method for obtaining a deeper and more accurate look into the molecular underpinnings of individual tumors in oncology.
 |
|
|